tldrdaily.news logo

Amgen's Weight-Loss Drug Faces Challenges and Adjustments in Trials

1 min read
Source: Barron's
Amgen's Weight-Loss Drug Faces Challenges and Adjustments in Trials
Photo: Barron's
TL;DR Summary

Amgen's shares dropped after disappointing trial results for its weight-loss drug MariTide, which showed high discontinuation rates due to gastrointestinal side effects, especially at higher doses, despite promising efficacy in weight loss; the company plans to adjust its Phase 3 trial strategy to mitigate these issues.

Topics:business#amgen#business#gastrointestinal-side-effects#maritide#trial-results#weight-loss-drug
Share this article
  1. Amgen Shares Fall on Weight-Loss Drug Tummy Troubles  Barron's
  2. Monthly weight loss drug helps people lose 20% of body weight, trial finds  NBC News
  3. Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing  STAT
  4. ADA25: Tweaked dosing schedule for MariTide cuts vomiting rates nearly in half  FirstWord Pharma
  5. Amgen gears up for phase 3 trial of monthly weight-loss drug MariTide amid mixed investor sentiment  Yahoo Finance

Reading Insights

Total Reads

0

Unique Readers

2

Time Saved

2 min

vs 2 min read

Condensed

88%

384 → 46 words

Want the full story? Read the original article

Read on Barron's